Business Context and Reporting Period
This Form 8-K Current Report was filed by Enliven Therapeutics, Inc. on June 13, 2025. The filing discloses updated positive data from the Phase 1 ENABLE clinical trial evaluating the company's lead product candidate, ELVN-001, for the treatment of chronic myeloid leukemia (CML). The data cutoff date for the clinical trial results was April 28, 2025.
Key Financial Metrics
This filing is a regulatory disclosure regarding clinical trial progress and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The company is identified as an emerging growth company.
Material Changes and Clinical Data Highlights
The primary material update concerns the efficacy and safety of ELVN-001 in a heavily pretreated patient population.
- Patient Demographics: As of April 28, 2025, 90 patients were enrolled across dose levels of 10 mg once daily to 80 mg twice daily. 80% of patients remained on study with a median treatment duration of approximately 29 weeks. The population was heavily pretreated, with 67% receiving three or more prior tyrosine kinase inhibitors (TKIs), including 58% with prior asciminib and 43% with prior ponatinib.
- Efficacy (24 Weeks): Among 53 evaluable patients with typical BCR-ABL1 transcripts and no T315I mutations, 47% (25 of 53) achieved Major Molecular Response (MMR). Specifically, 32% (13 of 41) achieved MMR, and 100% (12 of 12) of those who achieved it maintained it. Among patients resistant to their last TKI, 41% (14 of 34) achieved MMR.
- Comparative Performance: The achieved MMR rate of 32% compares favorably to historical Phase 1 data for asciminib (24%) and the ASCEMBL Phase 3 trial (25%), despite the Enliven trial population being more heavily pretreated.
- Safety Profile: ELVN-001 was well-tolerated. Only 3.4% of patients required dose reductions due to adverse events, and 4.6% discontinued due to adverse events. There were no treatment-related arterial occlusive events, and no evidence of enhanced cardiovascular toxicity was observed. The maximum tolerated dose was not reached.
- Pharmacokinetics: The profile supports once-daily dosing with flexible administration (with or without food) and low potential for drug-drug interactions.
Guidance, Outlook, and Risks
Outlook: The company expects to initiate its first head-to-head Phase 3 pivotal trial in 2026.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include the limited operating history, the ability to advance product candidates through clinical development, regulatory approval uncertainties, and the potential that early trial data may not predict later trial success. The company also notes reliance on third parties and the need to obtain additional capital to fund operations.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for complete statistical tables and safety data.
- Review the company's most recent Form 10-Q or 10-K for current cash runway and burn rate, as this 8-K does not contain financial data.
- Monitor the timeline for the anticipated 2026 Phase 3 trial initiation and any updates on patient enrollment.
- Assess the competitive landscape regarding other BCR::ABL1 TKIs, particularly in the context of the heavily pretreated patient population described.
- Confirm the status of intellectual property protection for ELVN-001 in the company's periodic reports.